References
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) [updated 2015] Available from: http://www.goldcopd.org/Accessed August 12, 2015
- World Health Organization–burden of COPD2015 Available from: http://www.who.int/respiratory/copd/burden/en/Accessed August 19, 2015
- BarrRGBourbeauJCamargoCARamFSInhaled tiotropium for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20052CD00287615846642
- TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
- O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
- TrivediRRichardNMehtaRChurchAUmeclidinium in patients with COPD: a randomised, placebo-controlled studyEur Respir J2014431728123949963
- Eklira Genuair EMA assessment report2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002211/WC500132663.pdfAccessed August 12, 2015
- Seebri Breezhaler EMA assessment report2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdfAccessed September 23, 2015
- INCRUSE ELLIPTA highlights of prescribing information2013 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDFAccessed August 12, 2015
- Summary of product characteristics: Incruse 55 micrograms inhalation powder2015 Available from: https://www.medicines.org.uk/emc/medicine/29394Accessed August 12, 2015
- ChapmanKRBeehKMBeierJA blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyBMC Pulm Med201414424438744
- BeierJKirstenAMMrozREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyCOPD201310451152223819698
- World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects2008 Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdfAccessed September 29, 2015
- CelliBRMacNeeWStandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J200423693294615219010
- DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
- Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
- WitekTJJrMahlerDAMinimal important difference of the transition dyspnoea index in a multinational clinical trialEur Respir J200321226727212608440
- JonesPWSt. George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
- KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
- IngelheimBSpiriva® 18 microgram, inhalation powder, hard capsule – package leaflet: information for the user2014 Available from: https://www.medicines.org.uk/emc/PIL.16286.latest.pdfAccessed October 20, 2015
- GSKIncruse® 55 micrograms inhalation powder, pre-dispensed – package leaflet: information for the user2015 Available from: https://www.medicines.org.uk/emc/PIL.29387.latest.pdfAccessed October 20, 2015
- DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
- SnapinnSMNoninferiority trialsCurr Control Trials Cardiovasc Med200011192111714400
- LewisJAMachinDIntention to treat – who should use ITT?Br J Cancer19936846476508398686
- ChurchABeeraheeMBrooksJMehtaRShahPDose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over studyBMC Pulm Med201414224393134
- DonohueJFAnzuetoABrooksJMehtaRKalbergCCraterGA randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPDRespir Med2012106797097922498110
- LittnerMRIlowiteJSTashkinDPLong-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20001611136114210764302
- Summary of Product Characteristics: Spiriva 18 microgram inhalation powder, hard capsule Available from: https://www.medicines.org.uk/emc/medicine/10039Accessed January 27, 2016
- SalmonMLuttmannMAFoleyJJPharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseasesJ Pharmacol Exp Ther2013345226027023435542
- PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin20092582043204819569976